At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 66 enrolled
Drug / intervention
PF-00299804 +1 moredrug
Likely dose
PF-00299804 45 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 2, OPEN-LABEL, TWO ARM TRIAL TO EVALUATE THE EFFICACY OF PF-00299804 IN PATIENTS WITH ADVANCED NSCLC AFTER FAILURE OF AT LEAST ONE PRIOR CHEMOTHERAPY REGIMEN AND FAILURE OF PRIOR TREATMENT WITH ERLOTINIB
In Brief
A Phase 2 clinical trial evaluating PF-00299804 for Carcinoma, Non Small Cell Lung. Completed, enrolled 66 participants across 19 sites.
Detailed Summary
To assess the antitumor efficacy measured by the objective response rate of oral PF-00299804 taken daily, as single agent in patients with advanced NSCLC who failed at least one chemotherapy + erlotinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCarcinoma, Non Small Cell Lung
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 2007
Enrollment StartApr 2008
Primary CompletionMar 2010
Study CompletionJun 2012
TodayJul 2026
First PostedOct 23, 2007
Enrollment StartApr 29, 2008
Primary CompletionMar 16, 2010
Study CompletionJun 11, 2012
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 18.7 years ago
Interventions
PF-00299804drug
PF-00299804 orally at 45 mg daily, on continuous schedule
PF-00299804drug
PF-00299804 orally at 45 mg daily, on continuous schedule